DIA’s Annual Canadian Meeting: Thinking Globally, Acting Locally for The Well-Being of the Patient

While regulators have developed avenues to provide patients early access to new therapies ie priority review, NoC with conditions, it is not as obvious what the post NoC market Access Stakeholders ie Drug Programs, Public and Private have/are doing. This session will look at various Market Access Stakeholders, their role in the Market Access process, their responsibility to patients within their jurisdiction and how their HTA review aligns to their patient responsibility.